跳转至内容
Merck

G1043

Sigma-Aldrich

Guanfacine hydrochloride

≥98% (HPLC)

别名:

N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C9H9Cl2N3O · HCl
CAS号:
分子量:
282.55
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

颜色

white

溶解性

H2O: soluble 12 mg/mL at 60 °C

创始人

Promius

SMILES字符串

Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl

InChI

1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H

InChI key

DGFYECXYGUIODH-UHFFFAOYSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

应用

Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.

生化/生理作用

Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.
α-2 noradrenergic receptor agonist.

特点和优势

This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Sophie Duong et al.
Expert opinion on drug metabolism & toxicology, 8(5), 543-552 (2012-03-15)
Pharmacotherapy is frequently used to treat symptoms of attention-deficit/hyperactivity disorder (ADHD), the most common neurobehavioral disorder of childhood. The typically prescribed agents for ADHD have varying durations of effect and degrees of efficacy. The broad range of pharmacological treatments available
Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast
Easton N, et al.
Psychopharmacology, 189(3), 369-385 (2006)
Yuanyuan Li et al.
Bioanalysis, 3(22), 2501-2514 (2011-11-30)
Dried blood spot (DBS) technology was evaluated for the quantitative determination of guanfacine in human blood in clinical studies. A very sensitive DBS assay has been developed using HPLC coupled with an AB Sciex 5500 QTRAP® (Applied Biosystems/MDS Sciex, ON
Sandra Bond Chapman et al.
The journals of gerontology. Series A, Biological sciences and medical sciences, 67(7), 773-780 (2012-05-10)
Human cognitive aging has been too long neglected and underappreciated for its critical importance to quality of life in old age. The articles in this session present novel approaches to improving cognitive function in normal aging persons with drugs and
Floyd R Sallee et al.
Journal of child and adolescent psychopharmacology, 22(3), 206-214 (2012-05-23)
Extended-release guanfacine (GXR) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. This post-hoc analysis further examines the effects of GXR on hyperactivity-impulsivity and inattentiveness. Data from two large double-blind placebo-controlled pivotal trials

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门